Semaglutide
STUB — Semaglutide has not been written up yet. Machine-resolvable fields below are populated from PubChem and PubMed; every judgement (mechanism, claims, evidence appraisal) is still missing.
Sequence
No sequence has been verified against a primary source.
How good is the evidence
STUB — evidence has not been appraised. The counts below reflect only what PubMed labelled outright in the sampled records and are a floor, not a total.
The studies themselves
| Study | Design | Subjects | Quality |
|---|---|---|---|
Safety of Semaglutide
Smits MM, Van Raalte DH · Frontiers in endocrinology · 2021
PMID 34305810
|
narrative_review / mixed | Mechanistic
risk of bias: unclear
| |
Semaglutide for the treatment of obesity
Chao AM, Wadden TA · Trends in cardiovascular medicine · 2023
PMID 34942372
|
narrative_review / mixed | Mechanistic
risk of bias: unclear
| |
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Davies M, STEP 2 Study Group · Lancet (London, England) · 2021
PMID 33667417
|
rct / human | Mechanistic
risk of bias: unclear
| |
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
Tan HC, Marquez MM · Journal of the ASEAN Federation of Endocrine Societies · 2022
PMID 36578889
|
systematic_review / mixed | Mechanistic
risk of bias: unclear
|
What we do not know
- This entry is a stub: no claim, mechanism, or evidence appraisal has been written.
- No dose from any cited study is recorded, because no full text has been read.
- The amino-acid sequence has not been verified against a primary source.